Abivax S.A. Stock
Price
Target price
€10.06
€10.06
-3.380%
-0.35
-3.380%
-
18.09.24 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abivax S.A. Stock
Abivax S.A. took a tumble today and lost -€0.350 (-3.380%).
Our community identified positive and negative aspects for Abivax S.A. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Abivax S.A. stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.
Pros and Cons of Abivax S.A. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | -3.380% | - | - | - | - | - | - |
| Valneva SE | -0.220% | -12.588% | -20.047% | -57.103% | -42.629% | -76.414% | -10.588% |
| Nanobiotix | 0.830% | -0.820% | -2.026% | -51.156% | -32.212% | -57.375% | -53.204% |
| Transgene S.A. | 0.590% | -2.677% | 5.492% | -40.607% | -24.030% | -58.785% | -41.628% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax presents first-half 2024 financial results
EQS-News: Abivax presents first-half 2024 financial results
EQS-News: Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
EQS-News: Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
EQS-News: Abivax Provides Operational and Key Program Update
EQS-News: Abivax Provides Operational and Key Program Update